Furthermore, our data suggest that intracellularly acting inhibitors against VEGF and its receptor VEGFR1 might be a more effective therapeutic method for breast cancer patients as compared to the externally acting inhibitors. The gene discussed is FLT1; the disease is breast carcinoma.